The company is trying again after receiving a complete response letter from the FDA last year requested more data.
An analysis from the FLEX study showed that only patients in MammaPrint's highest risk category benefitted from the addition ...
The firm's newly launched Cas-CLEAR platform uses Cas12a2 nucleases to recognize and kill cancer cells expressing certain genetic signatures.
NEW YORK – Australia's quick clinical trial startup process has drawn biotechs and pharma companies from around the world for over a decade, but the hub has taken on new significance for Chinese ...
The drugmaker made its decision after reviewing clinical and non-clinical studies, and said it's committed to exploring other treatment approaches.
The gene therapy for multiple sulfatase deficiency was one of the preclinical programs the Bespoke Gene Therapy Consortium selected for its pilot.
Current Chemolab equity holders will own approximately 32 percent of the combined company' shares and Scipher equity holders will own 68 percent.
Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...
An arbitration panel ruled Prime did not violate an agreement with Beam when it developed PM647, for which Prime plans to launch a clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results